Comparative Pharmacology
Head-to-head clinical analysis: CEFZIL versus KEFTAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFZIL versus KEFTAB.
CEFZIL vs KEFTAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefprozil inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
Cephalexin binds to penicillin-binding proteins (PBPs) on the bacterial cell wall, inhibiting transpeptidation and disrupting peptidoglycan cross-linking, leading to cell lysis via autolytic enzymes.
500 mg orally twice daily for 10 days; for uncomplicated skin infections, 250 mg twice daily or 500 mg once daily.
Cefuroxime axetil (KEFTAB) 250-500 mg orally twice daily for 7-10 days. For uncomplicated urinary tract infections: 250 mg twice daily; for acute otitis media: 500 mg twice daily.
None Documented
None Documented
1.2-1.5 hours in healthy adults; prolonged in renal impairment (e.g., up to 6-8 hours in severe renal failure)
0.8-1.2 hours (prolonged to 6-8 hours in renal impairment; requires dose adjustment for CrCl <50 mL/min)
Renal: 80-91% unchanged in urine; biliary/fecal: minimal (<5%)
Renal: 90-95% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic